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Abstract
Introduction Cough in bronchiectasis is associated with
significant impairment in health status. This study aimed to
quantify cough frequency objectively with a cough monitor
and investigate its relationship with health status. A sec-
ondary aim was to identify clinical predictors of cough
frequency.
Methods Fifty-four patients with bronchiectasis were
compared with thirty-five healthy controls. Objective 24-h
cough, health status (cough-specific: Leicester Cough
Questionnaire LCQ and bronchiectasis specific:
Bronchiectasis Health Questionnaire BHQ), cough severity
and lung function were measured. The clinical predictors of
cough frequency in bronchiectasis were determined in a
multivariate analysis.
Results Objective cough frequency was significantly raised
in patients with bronchiectasis compared to healthy con-
trols [geometric mean (standard deviation)] 184.5 (4.0) vs.
20.6 (3.2) coughs/24-h; mean fold-difference (95% confi-
dence interval) 8.9 (5.2, 15.2); p\ 0.001 and they had
impaired health status. There was a significant correlation
between objective cough frequency and subjective mea-
sures; LCQ r = -0.52 and BHQ r = -0.62, both
p\ 0.001. Sputum production, exacerbations (between
past 2 weeks to 12 months) and age were significantly
associated with objective cough frequency in multivariate
analysis, explaining 52% of the variance (p\ 0.001).
There was no statistically significant association between
cough frequency and lung function.
Conclusions Cough is a common and significant symptom
in patients with bronchiectasis. Sputum production, exac-
erbations and age, but not lung function, were independent
predictors of cough frequency. Ambulatory objective
cough monitoring provides novel insights and should be
further investigated as an outcome measure in
bronchiectasis.
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Abbreviations
LCM Leicester cough monitor
LCQ Leicester Cough Questionnaire
HRQOL Health-related quality of life
VAS Visual analogue scale
FEV1 Forced expiratory volume in 1 s
FVC Forced vital capacity
SD Standard deviation
COPD Chronic obstructive pulmonary disease
IPF Idiopathic pulmonary fibrosis
SGRQ St Georges Respiratory Questionnaire
BHQ Bronchiectasis Health Questionnaire
CT Computerised tomography
SD Standard deviation
IQR Interquartile range
CI Confidence interval
Introduction
Bronchiectasis is a chronic condition that is characterised
by dilated and often thick walled bronchi [1, 2]. Cough is a
predominant symptom of bronchiectasis and is worse
during exacerbations [3]. Cough in bronchiectasis is asso-
ciated with significant impairment in health-related quality
of life (HRQOL) [4]. Adverse symptoms associated with
cough include incontinence, syncope, chest pain and social
embarrassment [5, 6].
The development of ambulatory cough monitoring
devices has facilitated the objective assessment of cough
frequency [7, 8]. Recent studies in chronic respiratory
disorders such as chronic obstructive pulmonary disease
(COPD) and sarcoidosis have reported that patients
cough frequently, and this is associated with impaired
HRQOL [8, 9]. Objective cough frequency is also raised
in tuberculosis and has been linked to its transmission
[10–12]. An advantage of objective cough monitoring
over subjective outcome measures is that it is not sus-
ceptible to the perception of cough severity and reflects
actual coughing. There is a paucity of studies that have
investigated objective cough frequency in bronchiectasis.
The aim of this pilot study was to investigate cough
frequency objectively with 24-h cough monitoring and its
association with self-reported cough severity and
HRQOL. We also investigated clinical predictors of
objective cough frequency.
Methods
Subjects and Clinical Characterisation
Consecutive adult patients with bronchiectasis were recruited
prospectively from secondary care (King’s College Hospital)
and tertiary care (Royal Brompton Hospital) specialist clinics
from November 2012 to August 2014. The diagnosis of
bronchiectasis was based on clinical characteristics, com-
puterised tomography (CT) scans and consistent with the
British Thoracic Society guidelines [1]. Exclusion criteria
were cystic fibrosis, upper respiratory tract infection or
exacerbation of bronchiectasis within the past two weeks,
current smokers, presence of other co-existing respiratory
conditions and angiotensin-converting enzyme inhibitor
medication. The presence of cough was not an inclusion
criterion. Demographics and clinical characteristics were
recorded with a structured questionnaire. Sputum colonisa-
tion status was recorded using the clinical records of the most
recent sputum analyses. Sputum bacterial colonisation status
was defined as at least 2 positive cultures, assessed a mini-
mum 3 months apart and within one year [13]. The objective
cough frequency data from 35 healthy controls (restricted to
age range of patients with bronchiectasis) from a previous
study were used for comparison [14]. All healthy subjects had
normal spirometric values and were non-smokers (never or
ex-smokers\10 pack year history) and asymptomatic. All
subjects gave informed written consent and the study was
approved by the local research ethics committee (NRES
Committee London - Queen Square, 12/LO/1437).
Cough Frequency Monitoring
Cough frequency was recorded with the Leicester Cough
Monitor (LCM). The LCM is a validated ambulatory cough
monitor that consists of a portable MP3 sound recorder and
free-field microphone, worn for 24 h in the patient’s own
environment [7, 15, 16]. The sound files were uploaded
onto a computer for automated analysis using customised
cough detection software described previously [17].
Coughs were detected as single events whether occurring
in isolation or bouts. Patients were asked to record the
times of physiotherapy airway clearance in a diary. The
cough monitor methodology used in this study was similar
to that of healthy controls [14].
Subjective Assessment of Cough, Sputum
and Health Status
The Leicester Cough Questionnaire (LCQ) was used to
assess the impact of cough on the patients’ HRQOL and the
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cough-specific visual analogue scale (VAS, 0–100 mm)
was used to assess cough severity. The LCQ is a validated
cough-specific HRQOL questionnaire for adults that has
been validated in bronchiectasis [4, 18]. It has 19 cough-
specific questions that are divided into three domains
(physical, psychological and social) and a 7-point Likert
response scale. Scores for each domain range from 1 to 7
and total score range is 3–21, with a higher score indicating
a better HRQOL. Sputum production was assessed with
item 2 from the St. Georges Respiratory Questionnaire
(SGRQ): ‘‘Over the past 4 weeks, I have brought up
phlegm (sputum): not at all/only with respiratory infections
vs. a few days a month, several days a week or most days a
week’’ [8, 19, 20]. Patients were also asked to complete
VAS scales for severity of breathlessness and sputum
production. HRQOL was assessed with a respiratory
questionnaire, SGRQ, and with a novel, validated, disease
specific HRQOL questionnaire, Bronchiectasis Health
Questionnaire (BHQ) [21–23]. The BHQ has 10 items and
patients respond on a 7-point Likert scale. This question-
naire generates a single total score, range 0–100, with
higher scores indicating better health status. Self-reported
frequency of antibiotic use for respiratory tract infections
was used as an indicator of the frequency of exacerbations
in the previous 12 months (excluding past 2 weeks). This
was assessed with item 10 of the BHQ: ‘‘In the last
12 months, I have taken antibiotics for a chest infection’’
(0, 1, 2, 3, 4, 5,[5 times) [21–23].
Lung function
Spirometry was measured clinically in accordance with
international guidelines [24].
Protocol
All patients completed the questionnaires and were set up
for 24-h cough monitoring on the first day. They returned
the cough monitor the next day at the same time.
Analysis
Data were analysed using Prism Version 5.0 for Windows
(GraphPad Software; San Diego, California, USA) and
SPSS Statistics Version 20.0 for Windows (IBM, SPSS
Inc; Chicago, Illinois, USA). The distribution of data was
assessed using the D’ Agostino and Pearson omnibus test.
Parametric data were expressed as mean (standard devia-
tion, SD), whereas non-parametric data were expressed as
median (interquartile range, IQR). The cough frequency
and count data were logarithmic-transformed and presented
as geometric mean (log SD). Parametrically distributed
data were analysed with independent sample t tests to
compare sample means, whereas comparison of non-para-
metric data was carried out using the Mann–Whitney
U test. All analyses included subjects with and without
cough unless otherwise stated. The normal ranges for
females and males have previously been reported; females
\5 coughs per hour and males\2 coughs per hour [14].
Correlations between variables were analysed with the
Pearson’s correlation coefficient (r) for parametric data and
the Spearman’s correlation coefficient (q) for non-para-
metric data. A p value of less than 0.05 was considered
statistically significant. Predictors of objective cough fre-
quency were assessed in patients with bronchiectasis using
Pearson’s and Spearman’s correlations and general linear
models. All subjects with bronchiectasis were included in
the univariate and multivariate analyses.
Results
Subject Characteristics
Fifty-seven patients with bronchiectasis were recruited for
this study. The characteristics of patients are shown in
Table 1. Two patients were excluded due to cough
recording duration less than 24-h and one participant was
unable to return the cough monitor device. Fifty-four
patients completed a 24-h cough monitoring. The most
common identified cause of bronchiectasis was post-in-
fection (30%). Forty-six percent of patients had idiopathic
bronchiectasis. Bacterial sputum colonisation (any micro-
organism) was present in 22 (41%) patients and Pseu-
domonas aeruginosa colonisation in 14 (26%). The pro-
portion of patients that reported taking antibiotic courses
for acute respiratory infections in the past 12 months were
as follows: 14% no courses, 10% one course, 12% two
courses, 21% three courses, 8% four courses, 12% five
courses and 23% of patients more than five courses.
Twenty-one percent of patients reported having an acute
hospital admission for their bronchiectasis in the previous
12 months.
Cough Frequency Monitoring
Bronchiectasis vs. Healthy Controls
Twenty-four hour cough counts were significantly higher in
patients with bronchiectasis compared to healthy individ-
uals; geometric mean (logSD) 184.5 (0.6) coughs vs. 20.6
(0.5) coughs respectively, mean fold-difference (95%
confidence intervals, CI) 8.9 (5.2, 15.2), p\ 0.001 (Fig. 1).
Forty-one (84%) patients with bronchiectasis had abnor-
mally raised cough frequency based on a previously
Lung (2017) 195:575–585 577
123
published normal range (females\5 coughs per hour and
males\2 coughs per hour) [7, 14].
Bronchiectasis
Daytime (awake) cough counts were significantly greater
than night-time (asleep) in patients with bronchiectasis;
geometric mean (logSD) of daytime coughs 164.4 (0.6) vs.
night-time coughs 14.2 (0.8), mean fold-difference (95%
CI) 11.6 (8.2, 16.2), p\ 0.001 (Fig. 2). The frequency and
impact of cough are presented in Table 2. Female patients
had significantly higher cough counts per 24 h compared to
male patients; geometric mean (logSD): 254.7 (0.5) coughs
vs. 91.4 (0.6) coughs, respectively, mean fold-difference
(95% CI) 2.8 (1.4, 5.7); p = 0.006, Fig. 1. There was no
significant difference in 24-h cough counts between
patients with idiopathic bronchiectasis and identified cause;
geometric mean (logSD) 240.5 (0.1) coughs vs. 146.6 (0.1),
respectively, geometric mean fold-difference (95% CI) 1.6
(0.1, 3.3), p = 0.165.
The impact of intentional coughing during home, self-
directed, airway clearance physiotherapy was assessed.
Twenty-eight patients with bronchiectasis reported per-
forming at least one self-physiotherapy session for airway
clearance during 24-h cough monitoring and twelve
reported performing C2 sessions. The median (IQR) self-
reported duration for each session was 20 (10, 50) minutes.
There was no significant difference between 24-h cough
counts in patients who reported doing airway clearance vs.
those who did not (n = 26); geometric mean (logSD) 146.6
(0.5) vs. 139.6 (0.6) coughs, respectively, mean fold-dif-
ference (95% CI) 1.7 (0.8, 3.4), p = 0.131. Geometric
Table 1 Demographic and
clinical characteristics of the
study participants
Bronchiectasis (n = 54) Healthy (n = 35)
Female, n (%) 37 (69) 18 (51)
Age, years# 60.5 (15.0) 49.8 (13.9)*
Body mass index, kg/m2 23.0 (20.0, 28.0)# 25.1 (22.6, 29.0)#
Smoking status, n (%)
Never smoker 42 (78) 35 (100)
Ex-smoker ([10 pack year) 12 (22) 0 (0)
Current smoker 0 (0) 0 (0)
Spirometry
FEV1 % predicted 70.7 (26.2) 93.4 (25.8)*
FEV1/FVC
# 65.2 (13.7) 79.68 (5.2)*
PSA colonisation 14 (25.6) –
Symptoms severity
Sputum VAS 28.0 (15.0, 54.0)# na
Dyspnoea VAS 26.5 (12.3, 61.8)# na
SGRQ
Symptoms 64.0 (19.1) na
Activities 50.1 (28.1) na
Impact 32.5 (21.1) na
Total 40.1 (20.1) na
BHQ 60.6 (11.7) na
Aetiology, n (%)
Idiopathic 25 (46.3) na
Post infectious 16 (29.6) na
Immunodeficiency 5 (9.3) na
Other 6 (11.1) na
ABPA 2 (3.7)
Data presented as mean (standard deviation, SD), n (%), or medians (interquartile range, IQR). Healthy
individuals’ data are historical [12]
ABPA allergic bronchopulmonary aspergillosis, BHQ Bronchiectasis Health Questionnaire, FEV1 forced
expiratory volume in the first second, FVC forced vital capacity, PSA P. aeruginosa, SGRQ St George’s
Respiratory Questionnaire, VAS visual analogue scale, na not applicable
# Data presented as medians (IQR)
* Indicates significant differences between the groups, p\ 0.05
578 Lung (2017) 195:575–585
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mean (logSD) cough counts during the hour in which air-
way clearance physiotherapy was performed was higher
than daytime cough frequency, but this was not statistically
significant; 21.7 (0.6) vs. 14.5 (0.5) coughs per hour,
respectively, geometric mean fold-difference (95% CI) 1.5
(0.8, 2.8), p = 0.203. There was no significant difference
between cough counts in the 2-h preceding and 2-h fol-
lowing airway clearance; geometric mean (logSD) 33.6
(0.5) vs. 31.0 (0.5) coughs, respectively, mean fold-dif-
ference (95% CI) 1.1 (0.7, 1.7), p = 0.728. It should be
noted that the study sample size was small for these sub-
analyses and potentially underpowered to detect
differences.
Cough Frequency of Sputum Producers (Bronchiectasis)
Thirty-six (66.7%) patients reported sputum production,
median (IQR) VAS for sputum severity was 45 (16, 64)
mm. The 24-h cough counts was significantly higher in
sputum producers compared to non-producers; geometric
mean (logSD) 281.2 (0.8) vs. 49.8 (0.2), respectively, mean
fold-difference (95% CI) 5.6 (1.6, 20.0), p = 0.013. The
cough severity VAS and cough-HRQOL (LCQ total)
scores in sputum producers compared to non-producers
were: median (IQR) VAS 33 (21, 68) vs. 28 (11, 52) mm,
respectively, p = 0.385 and median (IQR) LCQ total score
15.2 (10.7, 18.6) vs. 17.5 (14.6, 19.0), respectively,
p = 0.465.
The Relationship Between Cough Frequency
and Subjective Assessments of Cough, Sputum
and HRQOL (Bronchiectasis)
Patients with bronchiectasis reported a moderate cough
severity on VAS; median (IQR) 31 (16, 67) mm. Cough
impacted all domains of HRQOL, see Table 2. There was a
significant association between 24-h cough counts and
cough-specific HRQOL (LCQ total score q = -0.52,
p\ 0.001; Fig. 3); cough severity VAS (q = 0.54,
p\ 0.001; online resource 1); and sputum VAS (q = 0.50,
p\ 0.001; online resource 2). There was stronger corre-
lation between 24-h cough counts and bronchiectasis
HRQOL assessed with BHQ (r = -0.62, p\ 0.001;
Fig. 4) than SGRQ (total score r = 0.32, p = 0.031;
Table 3 and online resource 3).
Fig. 1 Comparison of 24-h cough counts between patients with
bronchiectasis (n = 54) and healthy individuals (n = 35). Data
presented as geometric mean (standard deviation, SD). Open circles
represent female participants. Closed circles represent male partici-
pants. Healthy individuals’ data are historical [11]. Objective cough
counts per 24 h were measured using the Leicester Cough Monitor.
There was a statistically significant difference in cough counts per
24 h between female and male participants (p = 0.006)
Fig. 2 Number of coughs per
hour during the 24-h cough
frequency recording in
bronchiectasis (n = 54) and
healthy participants (n = 35).
Data presented as geometric
mean (standard deviation, SD)
Objective cough counts per 24 h
were measured using the
Leicester Cough Monitor.
Healthy participants represented
in white, bronchiectasis
participants in black
Lung (2017) 195:575–585 579
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Clinical Predictors of Objective Cough Frequency
(Bronchiectasis)
Table 4 summarises the relationship between patient
characteristics and objective cough frequency in the uni-
variate and multivariate models. In the univariate analyses,
gender, reported sputum production and number of courses
of antibiotics for respiratory infections in past year corre-
lated significantly with cough frequency. There was a trend
towards significance for age and sputum colonisation with
P. aeruginosa. There was no significant relationship
between cough frequency and lung function (Table 4,
online resource 4 and online resource 5), smoking status
and aetiology of bronchiectasis. Significant influences on
objective cough frequency were further explored in a
multivariate model, including five of the most statistically
significant/near significance variables in univariate analysis
(gender, age, reported sputum production, P. aeruginosa
colonisation and antibiotics for respiratory infection fre-
quency). Incorporating gender, age, reported sputum pro-
duction, P. aeruginosa colonisation and antibiotic
frequency into the model explained 52% of the variance in
cough frequency (p\ 0.001). Age, reported sputum pro-
duction and frequency of antibiotics for respiratory infec-
tion remained significant predictors of cough frequency
within the multivariate model (Table 4). Gender
(p = 0.07) and sputum P. aeruginosa colonisation
(p = 0.06) approached statistical significance (Table 4).
Discussion
This is the first study to investigate 24-h objective cough
frequency in patients with bronchiectasis. Cough frequency
was increased compared to healthy individuals, and was
associated with significant impairment in HRQOL. Age,
sputum production and frequency of antibiotic use for
respiratory exacerbations were independent predictors of
cough frequency, explaining 52% of its variance. There
was no association between cough frequency and lung
function. The strongest association between objective
Table 2 Objective and subjective assessments of cough in patients
with bronchiectasis (n = 54) and healthy individuals (n = 35)
Cough outcome measure Bronchiectasis Healthy
Cough severity, median (IQR)
VAS cough 31.0 (15.8, 67.0) na
Impact on health status, median (IQR)
LCQ Physical 4.5 (3.2, 5.8) na
LCQ Psychological 5.3 (3.4, 6.3) na
LCQ Social 5.3 (4.3, 6.3) na
LCQ Total 15.3 (10.4, 18.5) na
Objective cough counts, geo mean (logSD)
24-h cough counts, n 184.5 (0.6) 20.6 (0.5)**
Daytime cough counts, n 164.4 (0.6) 13.4 (0.5)**
Night-time cough counts, n 14.2 (0.8) 6.5 (0.5)*
Data presented as median (interquartile range, IQR) or geometric
mean (logarithmic standard deviation, logSD)
LCQ Leicester Cough Questionnaire, geo mean geometric mean, na
not applicable
* p\ 0.05, ** p\ 0.001
Fig. 3 Relationship between
24-h cough counts and cough-
related health status, using the
Leicester Cough Questionnaire
(LCQ). q: Spearman’s
correlation coefficient. Health
status was measured using the
Leicester Cough Questionnaire.
Objective cough counts per 24 h
were measured using the
Leicester Cough Monitor
580 Lung (2017) 195:575–585
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cough frequency and patient-reported outcomes measures
was with the Bronchiectasis Health Questionnaire (BHQ).
The cough frequency of bronchiectasis patients was
significantly higher than in healthy individuals, comparable
with that published in previous studies of chronic
obstructive pulmonary disease and less than idiopathic
chronic cough [8, 25]. Patients with bronchiectasis had a
diurnal variation in cough frequency, being significantly
higher during the day compared with the night. This is
consistent with findings in patients with chronic cough and
healthy individuals [6, 7, 16, 17, 26, 27]. Patients with
bronchiectasis were older than healthy controls. It is unli-
kely that age alone was the major reason for the ninefold
difference in cough frequency in patients compared to
healthy controls. There was no significant relationship
between cough frequency and age in univariate analysis;
however, this was statistically significant in multivariate
analysis. The basis for this relationship with age is not
clear. There is no relationship with age reported in other
chronic respiratory disorders such as idiopathic pulmonary
fibrosis, sarcoidosis, COPD or healthy individuals
[8, 9, 14, 28]. There was an increase in cough frequency
during the hour in which patients self-reported performing
airway clearance physiotherapy at home, compared to the
average daytime cough frequency. This increase in cough
frequency was not statistically significant and represented a
small proportion of overall 24-h cough counts. There was
no significant difference in cough frequency in the 2 h
preceding home airway clearance compared with 2 h fol-
lowing this. This study wasn’t designed to investigate the
impact of airway clearance therapy and this should be
assessed in larger studies.
We found that age, sputum production and frequency of
antibiotics for respiratory infections were significant inde-
pendent predictors of objective cough frequency. Sputum
production was an independent predictor of cough fre-
quency similar to the findings reported by Sumner et al. in
COPD [8]. In contrast, Sinha et al. did not find such
association in sarcoidosis [9]. We did not investigate if
specific characteristics of sputum were associated with
cough frequency such as volume, colour and consistency;
this should be investigated in future. We found a weak but
statistically significant association between cough fre-
quency and the number of courses of antibiotics in the
Fig. 4 Relationship between
24-h cough counts and health
status, using the Bronchiectasis
Health Questionnaire (BHQ). r:
Pearson’s correlation
coefficient. Health status was
measured using the
Bronchiectasis Health
Questionnaire. Objective cough
counts per 24 h were measured
using the Leicester Cough
Monitor
Table 3 The association between 24-h cough counts and health
status in bronchiectasis (n = 54)
Questionnaire Correlation coefficient p value
SGRQ
Symptoms 0.320 0.025
Activity 0.210 0.161
Impact 0.352 0.017
Total 0.323 0.031
LCQ#
Physical -0.556 \0.001
Psychological -0.475 0.001
Social -0.487 \0.001
Total -0.520 \0.001
BHQ
Total -0.616 \0.001
Data presented as Pearson’s correlation coefficient (r), unless other-
wise stated
BHQ Bronchiectasis Health Questionnaire, LCQ Leicester Cough
Questionnaire, SGRQ St George’s Respiratory Questionnaire
# Correlation coefficient Spearman’s q
Lung (2017) 195:575–585 581
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previous one year for respiratory infections. The frequency
of antibiotics was however a significant independent pre-
dictor of cough frequency in multivariate analysis. A recent
study by Kapur et al. in children with bronchiectasis found
that self-reported cough severity and the presence of ‘‘wet
cough’’ were the strongest predictors for defining an
exacerbation, by a considerable margin amongst a wide
range of commonly used clinical makers [29]. The poten-
tial of objective cough monitoring for defining exacerba-
tions in research studies should be explored.
There was a weak association between cough frequency
and sputum colonisation with P. aeruginosa in univariate
and multivariate analysis, which approached statistical sig-
nificance. Larger studies are needed to investigate the effect
of airway micro-organism colonisation on cough since our
study was underpowered to investigate this. Cough reflex
sensitivity has been reported to be heightened in
bronchiectasis, and is associated with subjectively reported
cough severity, similar to other chronic respiratory disorders
such as sarcoidosis and idiopathic chronic cough [30, 31].
The sensitivity of the cough reflex may therefore be an
important determinant of cough frequency.We did not study
the mechanisms that may be important in determining the
frequency of cough, as this was beyond the scope of this
study. Future studies should investigate the association
between cough frequency and cough reflex sensitivity, air-
way hyper-responsiveness, airway inflammation and the
extent of bronchiectasis, mucus plugging and airway wall
thickening using CT scan scoring systems [7]. We did not
find an association between cough frequency and standard
lung function parameters, and this finding is similar to those
in COPD, idiopathic chronic cough and sarcoidosis [8, 9].
The assessment of cough in bronchiectasis is therefore likely
to require tools other than lung function measures.
A recent systematic review and meta-analysis reported
that cough is one of the most important determinants of
Table 4 Predictors of objective
cough frequency in patients
with bronchiectasis (n = 54)
Predictors of cough frequency Correlation coefficient or variance p value
Univariate analyses
Age r = 0.229 0.096
Sex 0.006*
Body mass index r = -0.082 0.594
Spirometry
FEV1 % predicted r = -0.139 0.362
FVC % predicted r = -0.131 0.392
FEV1/FVC r = 0.026 0.857
Aetiology of bronchiectasis 0.276
Smoking status (never/ex) 0.268
Sputum production 0.013
Sputum microbiology
Pseudomonas sputum colonisation (yes/no) 0.091
Exacerbation frequency (past 1 year) q = -0.327 0.029
Multivariate analyses
Model R2 = 52.0% <0.001
Sex -0.230 0.077
Age 0.279 0.016
Pseudomonas sputum colonisation 0.207 0.066
Sputum production 0.448 <0.001
Exacerbation frequency -0.284 0.028
Bold values indicate p values\0.05
Data represent the ability of variables observed for predicting cough frequency. Multivariate analysis was
carried out using variables that had statistically significant or nearly significant association with cough
frequency; sex, age, self-reported sputum production, sputum P. aeruginosa colonisation and exacerbation
frequency (past one year). Self-reported sputum production was assessed by item 2 of the St George’s
Respiratory Questionnaire [18]. Respiratory infections were assessed by self-reported frequency of
antibiotics courses for respiratory infections in the past year. q = Spearman’s correlation coefficients
FEV1 forced expiratory volume in the first second, FVC forced vital capacity, SGRQ St George’s Respi-
ratory Questionnaire, VAS visual analogue scale
* Cough frequency greater in females compared to males
582 Lung (2017) 195:575–585
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HRQOL in bronchiectasis [32]. Our study confirms that
HRQOL is significantly impaired in bronchiectasis. There
was only a moderate relationship between subjective and
objective assessments of cough. The poor association
between subjective and objective tools is further demon-
strated by our finding that despite a near fivefold difference
in cough frequency between sputum producers and non-
producers, the subjective assessments of cough were not
statistically different between these groups. This may
suggest that individuals with a dry cough are more troubled
by their cough. Subjective measures assess aspects of
cough different to those measured by objective instru-
ments, and perhaps are more important to patients since
they represent their perception of the condition. A number
of cough outcomes are now available to assess patients
with bronchiectasis. They are best used in combination to
assess cough comprehensively. Among all subjective tools,
the BHQ had the strongest association with objective
cough frequency, followed closely by the LCQ and VAS.
The weakest association was with the SGRQ. These find-
ings highlight the importance of using disease and symp-
tom-specific tools when assessing patients.
There are some limitations to our study. We studied a
small number of subjects and this may have led to clini-
cally relevant imbalances in variables. Therefore, our
findings need to be confirmed in larger studies. We did not
record treatment status of participants and this could have
impacted the frequency of cough. We did not assess
patients for potential causes of cough, such as laryngeal
and sinus disease, gastro-oesophageal reflux and asthma. It
is possible that the presence of gastro-oesophageal reflux
in some patients may have influenced cough frequency
since it is associated with increased frequency of exacer-
bations of bronchiectasis and sputum colonisation. The
purpose of this study was to investigate objective cough
frequency in unselected patients with bronchiectasis.
Future studies should assess the relationship between
cough frequency, aetiology, therapy and patho-physiolog-
ical mechanisms, such as airway hyper-responsiveness,
cough reflex sensitivity and airway inflammation. We did
not find an association between cough, and FEV1 or the
presence of airway colonisation with P. aeruginosa. These
severity markers have limitations when used to assess
disease severity and therefore future studies should assess
disease severity with validated tools, such as the
Bronchiectasis Severity Index (BSI), which was not
available at the time of study, FACED and the extent of
bronchiectasis on CT scanning [14, 33]. We did not record
MRC breathlessness scale that is required to calculate the
BSI. We also note that the tools developed to assess cough
frequency have not formally been validated in bronchiec-
tasis. Cough in a patient with bronchiectasis often sounds
different to that of idiopathic cough. It is not known
whether the characteristics of cough sounds in bronchiec-
tasis affects the ability of cough monitors to detect cough
compared to other cough disorders. We found a diurnal
variation in cough frequency, higher frequency in females
compared to males and a significant association with
subjective assessments of cough, consistent with chronic
dry cough disorders. Furthermore, the cough monitor was
able to identify differences in cough frequency between
patients reporting sputum production compared with non-
producers. Cough monitors have been used in a wide range
of respiratory conditions such as asthma [34], COPD [8],
chronic cough [7], IPF [28], acute upper respiratory tract
infection [15], sarcoidosis [9] and cystic fibrosis [35].
Future studies should investigate the performance of cough
detection monitors in bronchiectasis. It is possible that
some coughs detected with monitors where those of sur-
rounding subjects in the patients’ environment but we have
recently reported that the Leicester Cough Monitor is able
to discriminate patient from environmental coughs (cough
from subjects nearby) [36].
The findings of this study suggest that cough is common
in patients with bronchiectasis, and is associated with
significant impairment in HRQOL. Our data also suggest
that it is feasible to assess cough objectively with 24-cough
frequency monitors. Cough frequency was significantly
raised in patients with bronchiectasis compared to healthy
individuals. Age, sputum production and frequency of
antibiotic use for respiratory infections were independent
predictors of cough frequency. Objective cough frequency
monitoring should be investigated further as an outcome
measure in bronchiectasis.
Acknowledgements We would like to thank Tracey Fleming, Claire
Wood and the staff of the lung function unit, and respiratory phys-
iotherapists and doctors at King’s College Hospital and the Royal
Brompton Hospital. We also thank all of the patients who took part in
this study.
Funding Arietta Spinou’s PhD was financially supported by the
Greek State Scholarships Foundation (IKY). KFC, RW and ML were
supported by NIHR Respiratory Biomedical Research Unit at the
Royal Brompton NHS Foundation Trust and Imperial College Lon-
don. SSB, Aish Sinha, KL, CE and RG were supported by King’s
College Hospital, Research and Development, and London National
Institute for Health Research (NIHR)/Wellcome Trust King’s Clinical
Research Facility and the NIHR Biomedical Research Centre and
Dementia Unit at South London and Maudsley NHS Foundation Trust
and King’s College London. The views expressed are those of the
author(s) and not necessarily those of the NHS, the NIHR or the
Department of Health, UK.
Authors’ Contributions Conception and design: SSB, RG, KFC;
Participants screening: AS, SSB, NY, ML, RW, CE, KL; Study
recruitment: AS; Data analysis: AS, SSB, IDP, SM, AiS; Drafting
manuscript: AS, SSB, RG; Interpretation and revised manuscript: All.
Lung (2017) 195:575–585 583
123
Compliance with Ethical Standards
Conflict of interest SB reports that King’s College Hospital received
fees for cough monitor analysis for unrelated clinical trials. IDP
reports personal fees from GSK, AZ, Almirall, Novartis, Boehringer
Ingelheim, Aerocrine, Genentec, Regeneron, Roche and Teva, outside
the submitted work. KFC reports personal fees from Gilead, GSK,
Chiesi, Merck, Boehringer Ingelheim, and Astra-Zenecas outside the
submitted work. No other author has a financial relationship with a
commercial entity that has an interest in the subject of this
manuscript.
Ethical Approval All procedures performed in studies involving
human participants were in accordance with the ethical standards of
the institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
Informed Consent Informed consent was obtained from all indi-
vidual participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creative
commons.org/licenses/by/4.0/), which permits unrestricted use, distri-
bution, and reproduction in anymedium, provided you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Pasteur MC, Bilton D, Hill AT (2010) British Thoracic Society
guideline for non-CF bronchiectasis. Thorax 65(Suppl 1):i1–i58
2. Palombini BC, Villanova CA, Araujo E et al (1999) A pathogenic
triad in chronic cough: asthma, postnasal drip syndrome, and
gastroesophageal reflux disease. Chest 116(2):279–284
3. Habesoglu MA, Ugurlu AO, Eyuboglu FO (2011) Clinical,
radiologic, and functional evaluation of 304 patients with
bronchiectasis. Ann Thorac Med 6(3):131–136
4. Murray MP, Turnbull K, MacQuarrie S et al (2009) Validation of
the Leicester Cough Questionnaire in non-cystic fibrosis
bronchiectasis. Eur Respir J 34(1):125–131
5. Brignall K, Jayaraman B, Birring SS (2008) Quality of life and
psychosocial aspects of cough. Lung 186(Suppl 1):S55–S58
6. Raj AA, Birring SS (2007) Clinical assessment of chronic cough
severity. Pulm Pharmacol Ther 20(4):334–337
7. Birring SS, Fleming T, Matos S et al (2008) The Leicester Cough
Monitor: preliminary validation of an automated cough detection
system in chronic cough. Eur Respir J 31(5):1013–1018
8. Sumner H, Woodcock A, Kolsum U et al (2013) Predictors of
objective cough frequency in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 187(9):943–949
9. Sinha A, Lee KK, Rafferty GF et al (2016) Predictors of objective
cough frequency in pulmonary sarcoidosis. Eur Respir J
47(5):1461–1471
10. Turner R, Bothamley G (2015) Cough and the transmission of
tuberculosis. J Infect Dis 211:1367–1372
11. Loudon RG, Spohn SK (1969) Cough frequency and infectivity in
patients with pulmonary tuberculosis. Am Rev Respir Dis
99:109–111
12. Proan˜o A, Bravard MA, Lo´pez JW et al (2017) Dynamics of
cough frequency in adults undergoing treatment for pulmonary
tuberculosis. Clin Infect Dis 64:1174–1181
13. Chalmers JD, Goeminne P, Aliberti S et al (2013) The
bronchiectasis severity index. An international derivation and
validation study. Am J Respir Crit Care Med 189(5):576–585
14. Yousaf N, Monteiro W, Matos S et al (2013) Cough frequency in
health and disease. Eur Respir J 41(1):241–243
15. Lee KK, Matos S, Evans DH et al (2013) A longitudinal
assessment of acute cough. Am J Respir Crit Care Med
187(9):991–997
16. Lee KK, Savani S, Matos DH et al (2012) Four-hour cough
frequency monitoring in chronic cough. Chest 142(5):1237–1243
17. Birring SS, Matos S, Patel RB et al (2006) Cough frequency,
cough sensitivity and health status in patients with chronic cough.
Respir Med 100(6):1105–1109
18. Birring SS, Prudon B, Carr AJ et al (2003) Development of a
symptom specific health status measure for patients with chronic
cough: Leicester Cough Questionnaire (LCQ). Thorax
58(4):339–343
19. Wilson CB, Jones PW, O’Leary CJ et al (1997) Validation of the
St. George’s Respiratory Questionnaire in bronchiectasis. Am J
Respir Crit Care Med 156(2 Pt 1):536–541
20. Jones PW, Quirk FH, Baveystock CM et al (1992) A self-com-
plete measure of health status for chronic airflow limitation. The
St. George’s Respiratory Questionnaire. Am Rev Respir Dis
145(6):1321–1327
21. Spinou A, Patel A, Garrod R et al (2013) Understanding patients’
experience of living with non-cystic fibrosis bronchiectasis. ERS
Meeting Abstr 42:P1359
22. Spinou A, Siegert R, Patel A et al (2017) The development and
validation of the bronchiectasis health questionnaire (BHQ). Eur
Respir J. doi:10.1183/13993003.01532-2016
23. Spinou A, Siegert R, Patel A, et al. The development and vali-
dation of the bronchiectasis health questionnaire (BHQ). ERS
Meeting Abstr 2016
24. Miller MR, Hankinson J, Brusasco V et al (2005) Standardisation
of spirometry. Eur Respir J 26(2):319–338
25. Mitchell S, Garrod R, Clark L et al (2017) Physiotherapy, and
speech and language therapy intervention for patients with
refractory chronic cough: a multicentre randomised control trial.
Thorax 72(2):129–136
26. Hsu JY, Stone RA, Logan-Sinclair RB et al (1994) Coughing
frequency in patients with persistent cough: assessment using a
24 hour ambulatory recorder. Eur Respir J 7(7):1246–1253
27. Faruqi S, Thompson R, Wright C et al (2011) Quantifying
chronic cough: objective versus subjective measurements.
Respirology 16(2):314–320
28. Key AL, Holt K, Hamilton A et al (2010) Objective cough fre-
quency in idiopathic pulmonary fibrosis. Cough 6:4
29. Kapur N, Masters IB, Morris PS et al (2012) Defining pulmonary
exacerbation in children with non-cystic fibrosis bronchiectasis.
Pediatr Pulmonol 47(1):68–75
30. Torrego A, Haque RA, Nguyen LT et al (2006) Capsaicin cough
sensitivity in bronchiectasis. Thorax 61(8):706–709
31. Guan W, Gao Y, Xu G et al (2014) Capsaicin cough sensitivity
and the association with clinical parameters in bronchiectasis.
PLoS ONE 9(11):e113057
32. Spinou A, Fragkos KC, Lee KK et al (2016) The validity of
health-related quality of life questionnaires in bronchiectasis: a
systematic review and meta-analysis. Thorax 71(8):683–694
33. Martinez-Garcia MA, de Gracia J, Vendrell Relat M et al (2014)
Multidimensional approach to non-cystic fibrosis bronchiectasis:
the FACED score. Eur Respir J 43(5):1357–1367
34. Marsden PA, Satia I, Ibrahim B, Woodcock A, Yates L, Donnelly
I, Jolly L, Thomson NC, Fowler SJ, Smith JA (2016) Objective
cough frequency, airway inflammation, and disease control in
asthma. Chest 149(6):1460–1466
584 Lung (2017) 195:575–585
123
35. Smith JA, Owen EC, Jones AM, Dodd ME, Webb AK, Wood-
cock A (2006) Objective measurement of cough during pul-
monary exacerbations in adults with cystic fibrosis. Thorax
61(5):425–429
36. Kulnik ST, Williams NM, Kalra L, et al. Cough frequency
monitors: can they discriminate patient from environmental
coughs? J Thorac Dis 2016 (in press)
Lung (2017) 195:575–585 585
123
